Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edwards EVOQUE System in Tricuspid Regurgitation
NCT04482062Active, not recruiting
- Sponsor
- Edwards Lifesciences
- Start
- Apr 2021
- Primary completion
- Dec 2025
- Countries
- 2
01
Overview
Randomised, open-label trial in tricuspid valve regurgitation (TVR), sponsored by Edwards Lifesciences. Primary endpoints: Tricuspid Regurgitation grade reduction at 6 months, Hierarchical composite endpoint including KCCQ, NYHA, and 6MWD at 6 months and 1 more. Started Apr 2021; status: active, not recruiting.
02
Conditions
tricuspid valve regurgitation (TVR)
Beyond the preview
Go deeper on NCT04482062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482062.